NASDAQ · IMVT
Immunovant, Inc.
$29.64+$0.22 (+0.75%)
Immunovant, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.74% below the high.
Loading market information…
NASDAQ · DNTH · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Dianthus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Dianthus Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.94. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dianthus Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | -$0.82+4.65% vs estimate | $1.16M+44.13% vs estimate |
|---|
| Q4 2024 | Mar 11, 2025 | -$0.81+4.71% vs estimate | $1.33M+38.71% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.74-25.42% vs estimate | $2.17M+193.06% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $131.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.64+$0.22 (+0.75%)
Immunovant, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.74% below the high.
$30.53-$0.41 (-1.33%)
Vera Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.53% below the high.
$48.64-$1.86 (-3.68%)
AnaptysBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.78% below the high.
$12.57+$0.26 (+2.11%)
MoonLake Immunotherapeutics’s quoted price sits in the lower half of its reported 52-week range, 46.03% below the high.
$6.89-$0.24 (-3.37%)
Alumis Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.02% below the high.
$8.87-$0.19 (-2.1%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
$4.23-$0.05 (-1.05%)
Artiva Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.89% below the high.
$6.75+$0.06 (+0.9%)
Cartesian Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.65% below the high.
